New shigella vaccine shows promise in first human trials
NCT ID NCT05073003
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new vaccine designed to protect against severe diarrhea caused by Shigella bacteria. The vaccine was first given to adults in Europe, then to adults, children, and infants in Africa. Researchers checked for side effects and measured immune responses to find the best dose for infants, who are most at risk. The trial has been completed, and results will help decide the next steps in vaccine development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AltSonflex1-2-3 vaccine (targets Shigella sonnei and Shigella flexneri serotypes 1b, 2a, and 3a)
What this could lead to
If successful, this vaccine could help prevent severe, sometimes deadly diarrhea in young children in regions where Shigella is common.
What could go wrong
This was an early-stage trial focused on safety and immune response, not on proving the vaccine prevents disease. Larger, later-stage trials are needed to confirm effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Kericho, 20200, Kenya